CSIMarket
 


Keros Therapeutics Inc   (KROS)
Other Ticker:  
 

Keros Therapeutics Inc 's Tangible Leverage Ratio

KROS's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to net new borrowings of 24.36%, Tangible Leverage Ratio fell to 0.11, a new company high.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 18 other companies have achieved lower Tangible Leverage Ratio than Keros Therapeutics Inc in the IV Quarter 2023. While Tangible Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 85, from total ranking in the third quarter 2023 at 202 .

Explain Tangible Leverage Ratio?
What is KROS Market Share?
What are KROS´s Total Liabilities?


KROS Tangible Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Tangible Equity Change 19.75 % 22.74 % 54.47 % 58.83 % 14.08 %
Y / Y Total Liabilities Change 28.8 % 174.66 % 103.25 % 173.62 % 143.09 %
Tangible Leverage Ratio MRQ 0.11 0.1 0.09 0.08 0.11
KROS's Total Ranking # 85 # 202 # 126 # 163 # 221
Seq. Tangible Equity Change 12.29 % -9.32 % -8.09 % 27.96 % 15.1 %
Seq. Total Liabilities Change 24.36 % 1.19 % 2.02 % 0.32 % 165.2 %



Tangible Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 19
Healthcare Sector # 31
Overall Market # 85


Tangible Leverage Ratio Statistics
High Average Low
0.11 0.07 0.03
(Dec 31 2023)   (Dec 31 2020)




Financial Statements
Keros Therapeutics Inc 's Tangible Equity $ 332 Millions Visit KROS's Balance sheet
Keros Therapeutics Inc 's Total Liabilities $ 38 Millions Visit KROS's Balance sheet
Source of KROS's Sales Visit KROS's Sales by Geography


Cumulative Keros Therapeutics Inc 's Tangible Leverage Ratio

KROS's Tangible Leverage Ratio for the trailling 12 Months

KROS Tangible Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Tangible Equity TTM Growth 19.75 % 22.74 % 54.47 % 58.83 % 14.08 %
Y / Y Total Liabilities TTM Growth 28.8 % 174.66 % 103.25 % 173.62 % 143.09 %
Tangible Leverage Ratio TTM 0.1 0.1 0.08 0.08 0.07
Total Ranking TTM # 1 # 168 # 1 # 28 # 37
Seq. Tangible Equity TTM Growth 12.29 % -9.32 % -8.09 % 27.96 % 15.1 %
Seq. Total Liabilities TTM Growth 24.36 % 1.19 % 2.02 % 0.32 % 165.2 %


On the trailing twelve months basis Despite of the net new borrowings of 24.36% during the twelve months period ending in IV Quarter 2023 Keros Therapeutics Inc has managed to unchanged Tangible Leverage Ratio in the IV Quarter 2023 to 0.1, above the KROS's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 18, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Keros Therapeutics Inc . While Tangible Leverage Ratio total ranking has improved so far to 1, from total ranking in previous 12 month period at 168.

Explain Tangible Leverage Ratio?
What is KROS Market Share?
What are KROS´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 19
Healthcare Sector # 31
Within the Market # 1


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.11 0.07 0.03
(Dec 31 2023)   (Dec 31 2020)




Companies with similar Tangible Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Tangible Equity
Anebulo Pharmaceuticals Inc   0.31 $ 2.027  Millions$ 6.487  Millions
Zai Lab Limited  0.31 $ 240.177  Millions$ 782.729  Millions
Deciphera Pharmaceuticals Inc   0.28 $ 96.771  Millions$ 350.916  Millions
Zymeworks Inc   0.27 $ 116.074  Millions$ 427.506  Millions
Igc Pharma Inc   0.27 $ 2.091  Millions$ 7.871  Millions
Zentalis Pharmaceuticals Inc   0.26 $ 114.404  Millions$ 433.655  Millions
Praxis Precision Medicines Inc   0.26 $ 18.279  Millions$ 69.669  Millions
Aadi Bioscience Inc   0.26 $ 27.228  Millions$ 105.195  Millions
Avidity Biosciences Inc   0.26 $ 127.791  Millions$ 500.764  Millions
Aclaris Therapeutics Inc   0.25 $ 39.800  Millions$ 156.910  Millions
Procyon Corporation  0.25 $ 0.583  Millions$ 2.335  Millions
Prothena Corporation Public Limited Company  0.24 $ 135.017  Millions$ 561.365  Millions
Aurinia Pharmaceuticals Inc   0.24 $ 88.099  Millions$ 372.977  Millions
Regeneron Pharmaceuticals Inc   0.23 $ 5,801.500  Millions$ 24,934.500  Millions
Intra cellular Therapies Inc   0.23 $ 136.871  Millions$ 591.424  Millions
Corcept Therapeutics Inc  0.23 $ 114.812  Millions$ 506.705  Millions
Verona Pharma Plc  0.22 $ 55.886  Millions$ 248.738  Millions
Compass Pathways Plc  0.22 $ 50.243  Millions$ 225.744  Millions
Indaptus Therapeutics Inc   0.22 $ 2.672  Millions$ 12.076  Millions
Marker Therapeutics inc   0.22 $ 3.075  Millions$ 14.053  Millions
Kiniksa Pharmaceuticals ltd   0.21 $ 87.483  Millions$ 421.589  Millions
Aprea Therapeutics Inc   0.21 $ 3.510  Millions$ 16.954  Millions
Leap Therapeutics inc   0.21 $ 12.422  Millions$ 60.141  Millions
Tharimmune Inc   0.20 $ 1.815  Millions$ 9.131  Millions
Neurogene Inc   0.20 $ 36.549  Millions$ 186.024  Millions
United Therapeutics Corporation  0.20 $ 1,146.800  Millions$ 5,870.600  Millions
Roivant Sciences Ltd   0.19 $ 1,222.916  Millions$ 6,434.167  Millions
Siga Technologies Inc  0.19 $ 36.705  Millions$ 195.961  Millions
Incannex Healthcare Inc   0.18 $ 3.487  Millions$ 18.872  Millions
Glycomimetics Inc   0.18 $ 6.902  Millions$ 38.414  Millions

Date modified: 2024-02-29T15:42:30+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com